Literature DB >> 23205080

Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma.

Nina Ditsch1, Doris Mayr, Miriam Lenhard, Carolin Strauss, Andrea Vodermaier, Julia Gallwas, Doris Stoeckl, Monika Graeser, Tobias Weissenbacher, Klaus Friese, Udo Jeschke.   

Abstract

Non-steroidal nuclear receptors play a major role in breast cancer development. A correlation among, and possible prognostic function of, the members of the nuclear receptor superfamily has been discussed controversially over the years. Hence, we conducted a quantification of the different expression levels of the thyroid receptor (TR), retinoid X receptor (RXR), peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) in malignant breast tumour tissue samples. Patients diagnosed and treated for breast cancer between 1990 and 2000 were included. Receptor expression was detected by immunohistochemical staining. Correlation analyses for the expression of the receptors were performed for the clinical and histopathological data. The paraffin-embedded tissue from 82 breast cancer patients was available. The different steroid receptors showed varying results when correlated with known histopathological markers. TRα2 demonstrated the most significant correlations with steroid hormone receptors. Significant correlations between the major isoforms of TR, and between RXR, PPAR and VDR, were demonstrated in the patient sample. The immunohistochemical association of these receptors may provide the first proof of an interaction on the molecular level. This assumption awaits confirmation in studies with larger cohorts.

Entities:  

Year:  2012        PMID: 23205080      PMCID: PMC3506670          DOI: 10.3892/ol.2012.799

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  41 in total

1.  MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response.

Authors:  M W Kilgore; P L Tate; S Rai; E Sengoku; T M Price
Journal:  Mol Cell Endocrinol       Date:  1997-05-16       Impact factor: 4.102

Review 2.  Cellular estrogen activity: implications for pulsed estrogen therapy.

Authors:  J Carlstedt-Duke
Journal:  Maturitas       Date:  2001-06-15       Impact factor: 4.342

3.  Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients.

Authors:  Yaqin Ling; Xiaoying Xu; Jie Hao; Xiaoling Ling; Xiaopin Du; Xin Liu; Xingxu Zhao
Journal:  Cancer Genet Cytogenet       Date:  2010-01-15

4.  Progesterone and estrogen receptors as prognostic variables in breast cancer.

Authors:  B H Mason; I M Holdaway; P R Mullins; L H Yee; R G Kay
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

5.  Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies.

Authors:  Darius Dian; Wolfgang Janni; Christina Kuhn; Doris Mayr; Uwe Karsten; Ioannis Mylonas; Klaus Friese; Udo Jeschke
Journal:  Onkologie       Date:  2009-04-20

6.  Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells.

Authors:  Daniela Bonofiglio; Erika Cione; Hongyan Qi; Attilio Pingitore; Mariarita Perri; Stefania Catalano; Donatella Vizza; Maria Luisa Panno; Giuseppe Genchi; Suzanne A W Fuqua; Sebastiano Andò
Journal:  Am J Pathol       Date:  2009-07-30       Impact factor: 4.307

Review 7.  The use of steroïd hormone receptors in the treatment of human breast cancer: a review.

Authors:  C K Osborne; W L McGuire
Journal:  Bull Cancer       Date:  1979       Impact factor: 1.276

8.  Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer.

Authors:  Michael Friedrich; Roland Axt-Fliedner; Carlos Villena-Heinsen; Wolfgang Tilgen; Werner Schmidt; Jörg Reichrath
Journal:  Histochem J       Date:  2002 Jan-Feb

9.  Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.

Authors:  P Tontonoz; E Hu; B M Spiegelman
Journal:  Cell       Date:  1994-12-30       Impact factor: 41.582

10.  Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha.

Authors:  Isabel Conde; María V T Lobo; Javier Zamora; Julio Pérez; Francisco J González; Emilio Alba; Benito Fraile; Ricardo Paniagua; María I Arenas
Journal:  BMC Cancer       Date:  2008-06-19       Impact factor: 4.430

View more
  10 in total

1.  The prevalence of benign breast diseases in patients with nodular goiter and Hashimoto's thyroiditis.

Authors:  C Anil; T Guney; A Gursoy
Journal:  J Endocrinol Invest       Date:  2015-04-01       Impact factor: 4.256

2.  Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways.

Authors:  Sabine Heublein; Doris Mayr; Alfons Meindl; Martin Angele; Julia Gallwas; Udo Jeschke; Nina Ditsch
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

3.  Peroxisome proliferator-activated receptor and vitamin d receptor signaling pathways in cancer cells.

Authors:  Satoru Matsuda; Yasuko Kitagishi
Journal:  Cancers (Basel)       Date:  2013-10-21       Impact factor: 6.639

4.  Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.

Authors:  Sabine Heublein; Doris Mayr; Alfons Meindl; Alexandra Kircher; Udo Jeschke; Nina Ditsch
Journal:  J Exp Clin Cancer Res       Date:  2017-04-20

5.  The Prognostic Impact of Retinoid X Receptor and Thyroid Hormone Receptor alpha in Unifocal vs. Multifocal/Multicentric Breast Cancer.

Authors:  Alaleh Zati Zehni; Falk Batz; Aurelia Vattai; Till Kaltofen; Svenja Schrader; Sven-Niclas Jacob; Jan-Niclas Mumm; Helene Hildegard Heidegger; Nina Ditsch; Sven Mahner; Udo Jeschke; Theresa Vilsmaier
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

6.  Low thyroid hormone receptor alpha-2 (THRα-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality.

Authors:  Ann H Rosendahl; Jonas Manjer; Malte Sandsveden; Signe Borgquist
Journal:  Breast Cancer Res       Date:  2021-12-20       Impact factor: 6.466

7.  Subcellular Distribution of Thyroid Hormone Receptor Beta in Ovarian Cancer.

Authors:  Sabine Heublein; Udo Jeschke; Cornelia Sattler; Christina Kuhn; Anna Hester; Bastian Czogalla; Fabian Trillsch; Sven Mahner; Doris Mayr; Elisa Schmoeckel; Nina Ditsch
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

8.  Prognostic Relevance of Nuclear Receptors in Relation to Peritumoral Inflammation and Tumor Infiltration by Lymphocytes in Breast Cancer.

Authors:  Melitta B Köpke; Marie-Christine Chateau; Florence Boissière-Michot; Mariella Schneider; Fabian Garrido; Alaleh Zati-Zehni; Theresa Vilsmaier; Mirjana Kessler; Nina Ditsch; Vincent Cavaillès; Udo Jeschke
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

9.  Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients.

Authors:  Nina Ditsch; Sabine Heublein; Udo Jeschke; Cornelia Sattler; Christina Kuhn; Anna Hester; Bastian Czogalla; Fabian Trillsch; Sven Mahner; Jutta Engel; Doris Mayr; Elisa Schmoeckel
Journal:  J Cancer Res Clin Oncol       Date:  2020-06-12       Impact factor: 4.553

10.  Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor β1 Are Inversely Associated with Survival in Primary Breast Cancer.

Authors:  Wanting Shao; Christina Kuhn; Doris Mayr; Nina Ditsch; Magdalena Kailuweit; Verena Wolf; Nadia Harbeck; Sven Mahner; Udo Jeschke; Vincent Cavaillès; Sophie Sixou
Journal:  Int J Mol Sci       Date:  2020-01-03       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.